Key facts
- Notable investors include Suzhou Oriza Holdings Corporation, HSG (Hong Kong), CICC Capital, Sinovation Ventures, Yijing Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Noah AI (Decision/Risk Analysis)
- ·The full record, as it builds
Funding rounds
No funding rounds for Noah AI (Decision/Risk Analysis) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Noah AI (Decision/Risk Analysis)
Developer of an artificial intelligence agent intended to streamline knowledge discovery and analysis in life sciences in the healthcare industry. The company offers automated literature search, database integration, news aggregation, report generation, and task automation with a focus on trusted scientific and medical sources, enabling researchers, clinicians, and biotech professionals to reduce manual effort while maintaining domain-specific accuracy and regulatory compliance.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2023
- Website
- noahai.co/
- Ownership
- Privately Held (backing)
Noah AI (Decision/Risk Analysis) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Noah AI (Decision/Risk Analysis) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Noah AI (Decision/Risk Analysis) in its N-PORT filings yet. We sweep new filings monthly.